Arrowhead Research | ARWR - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 75.25M 1.52M 2026-06
Heron Therapeutics USD 29.47M 3.17M 2025-12
Incyte USD 1.57B 400.89M 2026-06
Ionis Pharmaceuticals USD 265M 22M 2026-06
Ligand Pharmaceuticals USD 100.41M 51.96M 2026-06
Merck USD 12.09B 1.24B 2026-03
Moderna USD -566M 792M 2026-03
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Novartis USD 11.24B 1.18B 2026-06
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
TG Therapeutics USD 199.14M 27.73M 2026-06
Ultragenyx Pharmaceutical USD 180M 74M 2026-06
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06
Xencor USD 51.22M 46.7M 2026-06